• Revenue: $48.6 million, an increase of approximately 18% compared to last year.
• Adjusted EBITDA: $6.5 million, up from $2.4 million last year.
• Gross Profit: $36.4 million, up from $31.7 million in Q3 2023.
• Gross Margin: 74.9%, down from 76.8% in the same period last year.
• Operating Expenses: Increased by 2.9% to $36.8 million.
• Sales and Marketing Expenses: Decreased by 1.3% to $18.9 million.
• Research and Development Expenses: Increased by 4.5% to $7 million.
• General and Administrative Expenses: Increased by 9.8% to $10.8 million.
• Net Loss: $1.9 million or 4 per share, compared to a net loss of $4.1 million or 10 per share in Q3 2023.
• Adjusted Net Income: $3.1 million or 7 per share, compared to $0.7 million or 1.1 per share last year.
• Cash Flow: Positive cash flow in Q3, with cash, cash equivalents, and investments at $30.5 million as of September 30th.
• Full Year Revenue Guidance: Maintained at $182 to $186 million.
• Full Year Gross Margin Guidance: Expected to be at the high end of the 74 to 76% range.

• Warning! GuruFocus has detected 4 Warning Signs with AXGN.

Release Date: November 07, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Axogen Inc (NASDAQ:AXGN) reported a strong third quarter with revenue growth of approximately 18% year-over-year, reaching $48.6 million.
• The company achieved an adjusted EBITDA of $6.5 million, a significant increase from $2.4 million in the previous year.
• Axogen Inc (NASDAQ:AXGN) completed the rolling submission process for the Biologic License Application (BLA) for its advanced nerve graft, with the FDA accepting the filing for substantive review.
• The company saw broad-based growth across its portfolio, including increased nerve reconstruction cases and adoption of new solutions like the AAG HA nerve protector and Avive Plus soft tissue matrix.
• Axogen Inc (NASDAQ:AXGN) maintained its full-year revenue guidance and expects to be at the high end of its gross margin guidance, reflecting confidence in its financial performance.

Negative Points

• Despite strong third-quarter performance, Axogen Inc (NASDAQ:AXGN) chose not to adjust its full-year guidance, which some analysts viewed as conservative.
• The company's gross margin decreased to 74.9% from 76.8% in the same period last year, attributed to product mix changes.
• Operating expenses increased by 2.9% year-over-year, driven by higher general and administrative costs, including stock-based compensation.
• The company reported a net loss of $1.9 million for the quarter, although this was an improvement from the previous year's loss.
• Potential risks include supply chain disruptions, as mentioned in the context of hurricane impacts, which could affect revenue.

Q & A Highlights

Q: Why did Axogen decide to reiterate the full-year guidance despite strong third-quarter performance? A: Michael Dale, CEO, explained that the decision was based on the company's commitment to demonstrate predictability and meet the public guidance already established. This approach is intended to build trust with stakeholders while the company works on future plans.

Q: What are the key steps Axogen is taking to achieve standard of care status for its products? A: Michael Dale, CEO, highlighted that achieving standard of care involves evidence generation, collaboration with medical societies, and payer coordination. These steps typically take three to five years and require specific plans for different applications of their products.

Q: How does Axogen plan to sustain growth beyond deepening penetration in primary accounts? A: Michael Dale, CEO, noted that while focusing on primary accounts is crucial, there is a large universe of potential sites for nerve repair. The company is working on business models to fully exploit these opportunities and sustain growth.

Q: What is the significance of the FDA's decision not to hold an advisory committee meeting for the BLA review? A: Michael Dale, CEO, speculated that the decision might reflect confidence in the product's safety and efficacy, given its history and evidence. However, he emphasized that the company did not receive specific reasons from the FDA.

Q: How does Axogen view the potential BLA approval's impact on the commercial landscape for its products? A: Michael Dale, CEO, stated that BLA approval is strategically important as it affirms the product's safety and efficacy, enabling market development efforts and pursuit of standard of care status. It also addresses payer concerns about the product's status.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.